Ontology highlight
ABSTRACT:
SUBMITTER: Ma GJ
PROVIDER: S-EPMC3564656 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature
Ma Guoguang Julie GJ Chi Eric E Ibrahim Joseph G JG Parker Robert A RA
Statistics in biopharmaceutical research 20120101 3
Developing a drug requires large investments, over many years, with dramatic increases in development costs at later stages. Thus, one wants to make a No Go decision on a compound early, unless evidence continues to suggest that the project will ultimately be successful, so that resources can be focused on the most promising compounds to benefit patients. Instead of predicting the probability of success of a Phase III study, our approach to this decision uses the Phase II study results to assess ...[more]